leisure time -WSS

leisure time

author：fashion 2025-09-30 00:45:13 - browse：6

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Printout prescription drug information shouldn’t go digital

hotspot

WSS

Novartis develops a rapidly manufactured CAR

Burning questions about Delta and the next phase of the Covid pandemic

Mass General, Mayo Clinic look to monetize custom

Hundreds of thousands march in Israel. Former security chiefs beg Netanyahu to halt legal overhaul

Doctors have an ethical obligation to be advocates

Novartis develops a rapidly manufactured CAR

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

After affirmative action ruling, medical educators look to 'holistic review'

Woman found dead after suspected bear encounter near Yellowstone, wildlife officials say

The cancer drug shortage isn’t new — and neither are the solutions

Severe heat forecast: Where scorching temperatures will persist over the next week

United colonoscopy coverage change 'may cost lives,' doctors say

Clinic falsely told dozens they had Alzheimer's, suits say

Affirmative action in medical school literally saved lives

PrEP can help anyone prevent HIV. Why do so few people take it?

Jerome Adams on the need for new antivirals for Covid

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

leisure time

The response to Covid

What causes osteoarthritis? Researchers study link to brain protein

Prior authorization reform is both possible and imperative

Mass General, Mayo Clinic look to monetize custom

Men with early prostate cancer can safely opt out of treatment

Transgender women dream of pregnancy via uterus transplants

hotspot

knowledge

hotspot

Wikipedia